Vanguard Global Advisers’s Iovance Biotherapeutics IOVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.96M Sell
199,604
-16,797
-8% -$120K ﹤0.01% 1012
2026
Q2
$900K Buy
216,401
+82,564
+62% +$314K ﹤0.01% 1808
2026
Q1
$470K Buy
+133,837
New +$428K ﹤0.01% 2078

Other funds holding IOVA

Vanguard Global Advisers's IOVA Position: Q3 2026 in Review

Vanguard Global Advisers reduced its Iovance Biotherapeutics (IOVA) stake by 7.8% in Q3 2026, selling an estimated $120K and leaving 199,604 shares worth $2.96M. The position accounts for ﹤0.01% of the portfolio, ranked #1012.

Vanguard Global Advisers first reported a position in IOVA in Q1 2026 and has held it in 3 quarters since. 335 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.

  • Vanguard Global Advisers held 199,604 shares of Iovance Biotherapeutics worth $2.96M as of Q3 2026.
  • Vanguard Global Advisers sold 16,797 Iovance Biotherapeutics shares in Q3 2026, an estimated $120K.
  • Iovance Biotherapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1012 holding.
  • Vanguard Global Advisers first reported a position in Iovance Biotherapeutics in Q1 2026 and has held it in 3 quarters since.
  • 335 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.